Open an account

Anika Therapeutics

ANIK · NASDAQ

$20.44+$0.22 (+1.09%)TodayMarket closed ·
Prev close $20.22

About ANIK

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 235 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

Employees
235
Headquarters
Bedford, Massachusetts
Listed
May 16, 1985
Sector
Health Care
Industry
Biotechnology
Website
anika.com

ANIK key statistics

Market cap
273.55M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
96.20K
Volume
362.96K
Open price
$20.22
High today
$20.63
Low today
$20.11
52 Week high
$22.88
52 Week low
$9.01

Anika Therapeutics (ANIK) at a glance

Anika Therapeutics (ANIK) last traded at $20.44, with a market cap of 273.55M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $20.11 and $20.63. The current price is 1.6% above the day's low and 0.9% below its high.

Volume so far is 362.96K shares, above the average of 96.20K shares a day.

Over the past year Anika Therapeutics has ranged from $9.01 to $22.88, and now sits 82% of the way up that range.

Anika Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.42 per share against an estimate of -$0.0816.

The average analyst price target is $23.46, 14.8% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $23.46
Low
$23.23
Now
$20.44
High
$24.15

ANIK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 257.8% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of -$0.0153
  2. Q4 FY24: reported -$1.50 per share against an estimate of -$0.3009
  3. Q1 FY25: reported -$0.34 per share against an estimate of -$0.1462
  4. Q2 FY25: reported -$0.28 per share against an estimate of -$0.2584
  5. Q3 FY25: reported -$0.16 per share against an estimate of -$0.2754
  6. Q4 FY25: reported $0.02 per share against an estimate of -$0.2193
  7. Q1 FY26: reported $0.27 per share against an estimate of -$0.1632
  8. Q2 FY26: reported $0.42 per share against an estimate of -$0.0816

ANIK news

  • Press releaseGlobe Newswire

    Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseGlobe Newswire

    Telix Strengthens Board with Additional Director Appointments

  • Press releasePRNewswire

    Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors

  • Press releaseGlobe Newswire

    ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders

  • Press releaseBusiness Wire

    ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.

  • Press releaseBusiness Wire

    ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP

  • Press releaseGlobe Newswire

    Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK

Similar companies

Companies in the same industry as Anika Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.